It's How Medicine Should Be®

Physician Profile

-or-

call (888) 352-RUSH for help arranging an appointment

Gary L. Schaer, MD

Specialty:
  • Cardiovascular Disease
  • Interventional Cardiology
  • Internal Medicine
Board Certification:
  • Cardiovascular Disease
  • Interventional Cardiology
  • Internal Medicine
Faculty Rank: Professor
Medical or Graduate Education: Yale University School of Medicine
Residency: New York Hospital-Cornell Medical Center - Internal Medicine
Fellowship: National Institutes of Health - Critical Care Medicine
  Georgetown University Hospital - Cardiology
Clinical Expertise:
  • Angina
  • Angiogram, coronary
  • Angioplasty
  • Coronary artery disease
  • Gene therapy, cardiovascular
  • Heart attack
  • Peripheral vascular disease (PVD)
  • Stem cell therapy, cardiovascular
  • Stent placement
Research Interests:
  • Clinical trials of new drugs and devices in interventional cardiovascular medicine
  • Gene therapy to stimulate angiogenesis
  • Cell therapies (stem cells, skeletal myoblasts) for heart failure following myocardial infarction
Languages Spoken:
  • Spanish
Google Map
  • University Cardiologists
  • Professional Building
  • 1725 W. Harrison St.
  • Suite 1159
  • Chicago, IL  60612
  • Phone: (312) 942-5020
  • Fax: (312) 942-4039
  • View Larger MapDriving Directions

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

  1. Adverse Outcomes in Hospitalized Patients Who Develop ST-elevation Myocardial Infarction.
    Richmond T, Holoshitz N, Haryani A, Purim-Shem-Tov Y, Sharma G, Schaer GL
    Crit Pathw Cardiol
    2014 Jun
    13(2):62-5.
  2. An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure.
    Penn MS, Mendelsohn FO, Schaer GL, Sherman W, Farr M, Pastore J, Rouy D, Clemens R, Aras R, Losordo DW.
    Circ Res. 2013
    2013 Mar 1
    112(5):816-25. doi: 10.1161/CIRCRESAHA.111.300440. Epub 2013 Feb 21.
  3. A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study.
    Povsic TJ, Junge C, Nada A, Schatz RA, Harrington RA, Davidson CJ, Fortuin FD, Kereiakes DJ, Mendelsohn FO, Sherman W, Schaer GL, White CJ, Stewart D, Story K, Losordo DW, Henry TD
    Am. Heart J.
    2013 Jun
    165(6):854-861.e2.
  4. Assessment of safety, accuracy, and human CD34+ cell retention after intramyocardial injections with a helical needle catheter in a porcine model.
    Kumar A, Haralampus CA, Hughes M, Rouy D, Cresswell N, Braun R, Turner D, Amrani D, Motlagh D, Schaer GL.
    Catheter Cardiovasc Interv. 2012
    2012 May 14. doi: 10.1002/ccd.24476. [Epub ahead of print]
  5. Achieving high quality in ST-segment elevation myocardial infarction care: one urban academic medical center experience.
    Purim-Shem-Tov YA, Melgoza N, Haw J, Schaer GL, Calvin JE, Rumoro DP.
    Crit Pathw Cardiol. 2012
    2012 Mar
    11(1):32-9. doi: 10.1097/HPC.0b013e31824303f1.
  6. Therapeutic angiogenesis for the management of refractory angina: current concepts.
    Attanasio S, Schaer G.
    Cardiovasc Ther. 2011
    2011 Dec
    29(6):e1-e11. doi: 10.1111/j.1755-5922.2010.00153.x. Epub 2010 Apr 9. Review.
  7. Outcomes of unselected recipients of sirolimus-eluting stents: the Cypher stent U.S. post-marketing surveillance registry.
    Bezerra H, Perin E, Berger P, Block P, Ramee S, Katz S, Kellet M, Dippel E, Schaer G, Britto S, Cohen S, Costa M.
    J Invasive Cardiol. 2010
    2010 Feb
    22(2):48-55.
  8. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.
    Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB Jr, Reisman MA, Schaer GL, Sherman W.
    J Am Coll Cardiol. 2009
    2009 Dec 8
    54(24):2277-86. doi: 10.1016/j.jacc.2009.06.055.
  • View Transcript

More Videos

Stem Cell Research for Heart and Vascular Diseases